SuperworthRockwell Medical profit margin RMTI
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −7.3%
- Operating margin, 12 months
- −6.5%
- Net margin on a year earlier
- −4.9 pts
- Peer median
- 3.7%
Over the twelve months to Jun 30, 2026, Rockwell Medical kept −7.3% of its revenue as net profit, with an operating margin of −6.5% and a gross margin of 17.7%.
Five years earlier its net margin was −52.7%.
The median for 4 large drugmakers of a similar size is 3.7%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −7.7% | −6.8% | 16.9% |
| FY2024 | −0.5% | 0.6% | 17.2% |
| FY2023 | −10.1% | −8.0% | 10.4% |
| FY2022 | −25.7% | −23.0% | 5.6% |
| FY2021 | −52.8% | −49.0% | −3.9% |
| FY2020 | −49.7% | −45.7% | 4.4% |
| FY2019 | −55.7% | −56.3% | 4.6% |
| FY2018 | −50.7% | −51.2% | −2.5% |
| FY2017 | −45.2% | −45.2% | 6.5% |
| FY2016 | −37.2% | −37.9% | 12.7% |
| FY2015 | −26.1% | −27.3% | 16.1% |
| FY2014 | −39.4% | −32.4% | 15.8% |
| FY2013 | −93.1% | −89.8% | 12.7% |
| FY2012 | n/a | n/a | 13.4% |
| FY2011 | −43.8% | −44.3% | 11.5% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −7.3% | −4.9 pts | −6.5% | |
| Q1 FY26 | −8.0% | −7.7 pts | −7.1% | |
| Q4 FY25 | −7.7% | −7.2 pts | −6.8% | |
| Q3 FY25 | −7.3% | −6.0 pts | −6.4% | |
| Q2 FY25 | −2.4% | +2.7 pts | −1.5% | |
| Q1 FY25 | −0.3% | +9.5 pts | 0.6% | |
| Q4 FY24 | −0.5% | +9.6 pts | 0.6% | |
| Q3 FY24 | −1.2% | +10.2 pts | 0.6% | |
| Q2 FY24 | −5.1% | +10.3 pts | −3.3% | |
| Q1 FY24 | −9.7% | +7.7 pts | −7.6% | |
| Q4 FY23 | −10.1% | +15.6 pts | −8.0% | |
| Q3 FY23 | −11.5% | +25.2 pts | −10.0% |
Against its peers
Companies in Drug Manufacturers - General nearest Rockwell Medical's size, closest first, today.
| Company | Profit margin |
|---|---|
| RMTIRockwell Medical | −7.3% |
| ATNMActinium Pharmaceuticals | n/m |
| SPROSpero Therapeutics | 15.7% |
| LFVNLifevantage | 2.8% |
| NATRNatures Sunshine Products | 3.7% |
| Peer median | 3.7% |
Where Rockwell Medical ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Rockwell Medical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.